Kelyniam Global Announces Q2 and Q3 Earnings
Canton, CT, December 06, 2014 --(PR.com)-- Kelyniam Global, Inc. (OTC Pink: KLYG), an innovative medical device design and manufacturing company, posted its 2nd & 3rd quarter sales at $436,865 and $455,401 respectively. The reduction in quarterly revenue can be directly attributed to company resources allocated to its recent acquisition of MED-ALLY, LLC and the development and implementation of enhanced efficiency processes now being used in the manufacturing of PEEK Optima cranial and cranial-facial implants. These manufacturing efficiencies substantially reduce materials usage and associated costs, which increases profit margins and company bottom line.
"This year has been a building and development year for Kelyniam. We have had to allocate some of our human resources to our goal of product diversification and expansion, but strongly believe these efforts are in the best interest of the company long term and will have significant effects on the overall value of Kelyniam Global, Inc.,” said Tennyson Anthony, president and CEO of Kelyniam Global. “With the acquisition of MED-ALLY, we have opened the door to being a leader in the neurostimulation field which is the most promising and exciting field in medicine today. There is incredible potential here and we are working to capitalize on that potential and realize a position at the top.” For more information go to www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (OTC: KLYG) is an innovative Medical Device Manufacturing Company specializing in the production of custom PEEK cranial and facial prosthetics and proprietary, implantable neuromodulation medical device systems. Its Engineering Division works diligently with medical professionals - allowing them to operate more effectively, improve patient care and surgical outcomes while reducing health care cost. Kelyniam is continually researching and developing new products, materials and processes to help patients live more active and productive lives.
Forward-Looking Statements
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.
Contact:
Christian Scarborough, www.inventivepr.net
christian@inventivepr.net
325-388-6263
"This year has been a building and development year for Kelyniam. We have had to allocate some of our human resources to our goal of product diversification and expansion, but strongly believe these efforts are in the best interest of the company long term and will have significant effects on the overall value of Kelyniam Global, Inc.,” said Tennyson Anthony, president and CEO of Kelyniam Global. “With the acquisition of MED-ALLY, we have opened the door to being a leader in the neurostimulation field which is the most promising and exciting field in medicine today. There is incredible potential here and we are working to capitalize on that potential and realize a position at the top.” For more information go to www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (OTC: KLYG) is an innovative Medical Device Manufacturing Company specializing in the production of custom PEEK cranial and facial prosthetics and proprietary, implantable neuromodulation medical device systems. Its Engineering Division works diligently with medical professionals - allowing them to operate more effectively, improve patient care and surgical outcomes while reducing health care cost. Kelyniam is continually researching and developing new products, materials and processes to help patients live more active and productive lives.
Forward-Looking Statements
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.
Contact:
Christian Scarborough, www.inventivepr.net
christian@inventivepr.net
325-388-6263
Contact
Kelyniam Global, LLC
Christian Scarborough
325-388-6263
www.kelyniam.com
Christian Scarborough
325-388-6263
www.kelyniam.com
Contact
Categories